Clinical Trials Register

Summary
EudraCT Number:	2018-003081-14
Sponsor's Protocol Code Number:	1368-0027
National Competent Authority:	Spain - AEMPS
Clinical Trial Type:	EEA CTA
Trial Status:	Completed
Date on which this record was first entered in the EudraCT database:	2019-12-20
Trial results	View results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Spain - AEMPS

A.2

EudraCT number

2018-003081-14

A.3

Full title of the trial

Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in preventing generalized pustular psoriasis (GPP) flares in patients with history of GPP

Effisayil™ 2: Ensayo fase IIb de búsqueda de dosis, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de BI 655130 (Spesolimab) en comparación con placebo en la prevención de brotes de psoriasis pustulosa generalizada (GPP) en pacientes con antecedentes de GPP

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

A study to test whether BI 655130 (Spesolimab) prevents flare-ups in patients with Generalized Pustular Psoriasis

Estudio para evaluar si BI 655130 (Spesolimab) previene brotes en pacientes con psoriasis pustulosa generalizada

A.4.1

Sponsor's protocol code number

1368-0027

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	Boehringer Ingelheim España, S.A.
B.1.3.4	Country	Spain
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Boehringer Ingelheim España, S.A.
B.4.2	Country	Spain
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	Boehringer Ingelheim Pharma GmbH & Co. KG
B.5.2	Functional name of contact point	CT Disclosure & Data Transparency
B.5.3	Address:
B.5.3.1	Street Address	Binger Strasse 173
B.5.3.2	Town/ city	Ingelheim am Rhein
B.5.3.3	Post code	55216
B.5.3.4	Country	Germany
B.5.4	Telephone number	+34934045100
B.5.5	Fax number	+34934045580
B.5.6	E-mail	clintriage.rdg@boehringer-ingelheim.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.2	Product code	BI 655130
D.3.4	Pharmaceutical form	Solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Spesolimab
D.3.9.2	Current sponsor code	BI 655130
D.3.9.3	Other descriptive name	MONOCLONAL ANTIBODY ANTI-IGG1
D.3.9.4	EV Substance Code	SUB31544
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	60
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.2	Product code	BI 655130
D.3.4	Pharmaceutical form	Solution for injection in pre-filled syringe
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Spesolimab
D.3.9.2	Current sponsor code	BI 655130
D.3.9.3	Other descriptive name	MONOCLONAL ANTIBODY ANTI-IGG1
D.3.9.4	EV Substance Code	SUB31544
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	150
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Solution for injection in pre-filled syringe
D.8.4	Route of administration of the placebo	Subcutaneous use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Generalized Pustular Psoriasis

Psoriasis pustulosa generalizada

E.1.1.1

Medical condition in easily understood language

Generalized Pustular Psoriasis

Psoriasis pustulosa generalizada

E.1.1.2

Therapeutic area

Diseases [C] - Skin and Connective Tissue Diseases [C17]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	21.0
E.1.2	Level	LLT
E.1.2	Classification code	10037159
E.1.2	Term	Psoriasis pustular
E.1.2	System Organ Class	100000004858

E.1.3

Condition being studied is a rare disease

Yes

E.2 Objective of the trial

E.2.1

Main objective of the trial

The primary objective of the trial is to demonstrate a non-flat curve and evaluate the dose-response relationship for 3 subcutaneous dosing regimens of BI 655130 (with each regimen consisting of a single loading dose and a separate maintenance subcutaneous dosing regimen) versus placebo, on the primary endpoint, the time to the first GPP flare onset up to week 48.

El objetivo principal del ensayo es demostrar la existencia de una curva de respuesta a la dosis no plana y evaluar la relación dosis-respuesta con 3 pautas posológicas subcutáneas de BI 655130 (cada pauta consiste en una dosis de carga única y una pauta posológica subcutánea de mantenimiento independiente) frente a placebo teniendo en cuenta el criterio principal de valoración, es decir, el tiempo transcurrido hasta el primer brote de GPP hasta la semana 48.

E.2.2

Secondary objectives of the trial

The secondary objective is to demonstrate superiority versus placebo for each of BI 655130 regimen on the primary endpoint, the time to the first GPP flare onset up to week 48, as well as the key secondary endpoint, the occurrence of at least one GPP flare up to 48 weeks.

El objetivo secundario es demostrar superioridad frente al placebo de cada dosis de BI 655130 respecto al criterio principal, el tiempo transcurrido hasta el primer brote de GPP hasta la semana 48, así como respecto al criterio secundario de valoración clave, la aparición de al menos un brote de PPG hasta la semana 48.

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

1. Patients with a known and documented history of GPP per ERASPEN criteria (see Section 3.3.1) regardless of IL36RN mutation status.

2. Patients with a GPPGA score of 0 or 1 at screening and randomization.

3. Male or female patients, aged 12 to 75 years at screening. For all patients, a minimum weight of 40 kg is required.

4. Signed and dated written informed consent and assent in accordance with ICH-GCP and local legislation prior to admission in the trial.

5. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the CTP as well as in the patient (or patient’s legal guardian) information.

Additional inclusion criteria will apply.

1. Pacientes con antecedentes conocidos y documentados de GPP según los criterios ERASPEN (véase el apartado 3.3.1), independientemente del estado de mutación de IL36RN.
2. Pacientes con una puntuación GPPGA de 0 o 1 en la selección y en la aleatorización.
3. Pacientes de ambos sexos, de edades comprendidas entre los 12 y los 75 años de edad en la selección. Se requiere un peso mínimo de 40 kg de todos los pacientes.
4. Consentimiento informado por escrito firmado y fechado y asentimiento, de conformidad con las normas de BPC de la ICH y la legislación local antes de la inclusión en el ensayo.
5. Las mujeres potencialmente fértiles deben querer y poder utilizar métodos anticonceptivos muy eficaces según la directriz M3 de la ICH (R2), es decir, aquellos con una tasa de fracaso baja, inferior al 1 % por año, cuando se emplean correctamente y de forma consistente. Se proporciona una lista de métodos anticonceptivos que cumplen con estos criterios en el protocolo, así como en la información para el paciente o padre(s) (o tutores legales del paciente).

Otros criterios de inclusión adicionales también aplicarán.

E.4

Principal exclusion criteria

1. Patients with SAPHO (Synovitis–acne–pustulosis–hyperostosis–osteitis) syndrome.

2. Patients with primary erythrodermic psoriasis vulgaris.

3. Severe, progressive, or uncontrolled hepatic disease, defined as >3-fold Upper Limit of Normal (ULN) elevation in AST or ALT or alkaline phosphatase, or >2-fold ULN elevation in total bilirubin.

4. Treatment with:
a. Any restricted medication as specified in the CTP, or any drug considered likely to interfere with the safe conduct of the study, as assessed by the investigator.
b. Any prior exposure to BI 655130 or another IL36R inhibitor biologic.

5. Increased risk of infectious complications (e.g. recent pyogenic infection, any congenital or acquired immunodeficiency (e.g. HIV), past organ or stem cell transplantation), as assessed by the investigator.

6. Relevant chronic or acute infections including active tuberculosis, human immunodeficiency virus (HIV) infection or viral hepatitis at the time of randomization. A patient can be re-screened if the patient was treated and is cured from the acute infection.

7. Active or Latent TB:
• Patients with active tuberculosis should be excluded
• Patients with a positive QuantiFERON® (or if applicable, T-Spot®) TB test during screening are excluded, unless the patient had previous diagnosis of active or latent TB and has completed appropriate treatment per the discretion of the local investigator within the last 3 years and at the latest at the time of screening (i.e. 2 to 4 weeks before study drug administration); patients may be re-screened once to meet this criterion)

8. History of allergy/hypersensitivity to the systemically administered trial medication agent or its excipients.

9. Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix.

10. Women who are pregnant, nursing, or who plan to become pregnant while in the trial. Women who stop nursing before the study drug administration do not need to be excluded from participating; they should refrain from breastfeeding for 16 weeks after the last study drug administration.

11. Major surgery (major according to the investigator’s assessment) performed within 12 weeks prior to receiving first dose of study drug or planned during the study, e.g. hip replacement, aneurynsm removal, stomach ligation, as assessed by the investigator.

12. Evidence of a current or previous disease, medical condition (including chronic alcohol or drug abuse or congestive heart disease or any condition) other than GPP, surgical procedure, psychiatric or social problems, medical examination finding (including vital signs and electrocardiogram (ECG)), or laboratory value at the screening outside the reference range that in the opinion of the investigator is clinically significant.

Additional exclusion criteria will apply.

1. Pacientes con síndrome SAPHO (sinovitis, acné, pustulosis, hiperostosis, osteítis).
2. Pacientes con psoriasis eritrodérmica vulgar primaria.
3. Enfermedad hepática grave, progresiva o no controlada, definida como un aumento de >3 veces el límite superior de la normalidad (LSN) de la cantidad de AST, ALT o fosfatasa alcalina, o de >2 veces el LSN de la cantidad de bilirrubina total.
4. Tratamiento con:
a. Cualquier medicación restringida tal y como se especifica en el protocolo, o cualquier medicación que considere el investigador sea posible que pueda interferir con la seguridad del estudio.
b. Cualquier exposición previa a BI 655130 u otro inhibidor biológico de IL36R.
5. Riesgo incrementado de infecciones (ej. infección piogénica reciente, cualquier inmunodeficiencia adquirida o congénita (ej. VIH), trasplante de órgano o célula madre), tal y como considere el investigador.
6. Infecciones agudas o crónicas relevantes incluyendo tuberculosis activa, VIH o hepatitis vírica en el momento de la aleatorización. Se puede volver a evaluar la participación del paciente si este se trata y cura de la infección aguda.
7. TB activa o latente:
- Los pacientes con tuberculosis activa deben ser excluidos.
- Los pacientes con test positivo de TB QuantiFERON® (o si aplica T-Spot®) durante la selección deben ser excluidos, excepto que el paciente haya sido diagnosticado previamente de TB activa o latente y haya finalizado el tratamiento apropiado, con criterio del investigador local, dentro de los últimos 3 años (ej. de 2 a 4 semanas antes de la administración del medicamento en investigación); los pacientes deben volver a ser evaluados para cumplir este criterio.
8. Alergia/hipersensibilidad histórica a la administración sistémica de la medicación del ensayo o a sus excipientes.
9. Cualquier neoplasia documentada activa o sospecha de neoplasia, o historia de neoplasia en los 5 años previos a la selección, excepto carcinoma de piel de células escamosas o basales tratados apropiadamente o carcinoma in situ del cuello uterino.
10. Mujeres que están embarazadas o en periodo de lactancia, que tengan planeado quedarse embarazadas durante el ensayo. Las mujeres que paren la lactancia antes del ensayo no deben ser excluidas, deben esperar a seguir con la lactancia 16 semanas después de la última administración del medicamento del ensayo.
11. Cirugía importante (importante según la evaluación del investigador) realizada en las 12 semanas previas a la primera dosis de la medicación del ensayo o planeada durante el ensayo: ej. reemplazo de cadera, eliminación de aneurisma, extracción de aneurisma, ligadura de estómago (según el investigador convenga).
12. Evidencia de enfermedad previa o actual, o condición médica (incluyendo alcoholismo crónico o drogadicción o insuficiencia cardíaca o cualquier otra condición) diferente a GPP, procedimiento quirúrgico, problemas sociales o psiquiátricos, hallazgo durante la examinación médica (signos vitales o ECG), o valor del laboratorio que durante la selección esté fuera del rango de referencia que en opinión del investigador sea clínicamente significativo.

Otros criterios de exclusión adicionales también aplicarán.

E.5 End points

E.5.1

Primary end point(s)

1) Time to first Generalized Pustular Psoriasis (GPP) flare (defined by increase in Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score by ≥ 2 from baseline and the pustular component of GPPGA ≥ 2) up to week 48.

1) Tiempo transcurrido hasta el primer brote de GPP (definido por el aumento de la puntuación GPPGA en ≥2 respecto al periodo basal y el componente pustuloso de GPPGA ≥2) hasta la semana 48

E.5.1.1

Timepoint(s) of evaluation of this end point

1) up to week 48

1) hasta la semana 48

E.5.2

Secondary end point(s)

1) The occurrence of at least one GPP flare (defined by increase in GPPGA score by ≥ 2 from baseline and the pustular component of GPPGA ≥ 2) up to week 48.
2) Time to first worsening of Psoriasis Symptom Scale (PSS) up to week 48 defined as a 4-point increase in total score from baseline. Intake of rescue medication, or investigator-prescribed SoC, will be considered as onset of a worsening.
3) Time to first worsening of Dermatology Quality of Life Index (DLQI) up to week 48 defined as a 4-point increase in total score from baseline. Intake of rescue medication, or investigator-prescribed SoC, will be considered as onset of a worsening.
4) Sustained remission, defined as a patient with a GPPGA score of 0 or 1 (clear or almost clear) at all visits up to week 48, without intake of rescue medication, or investigator-prescribed SoC.
5) The occurrence of treatment emergent adverse events (TEAEs)

1) Aparición de al menos un brote de GPP (definido por el aumento de la puntuación GPPGA en ≥2 respecto al periodo basal y el componente pustuloso de GPPGA ≥2) hasta la semana 48.
2) Tiempo transcurrido hasta la primera manifestación de empeoramiento de la Escala de síntomas de psoriasis (PSS) hasta la semana 48, definido como un aumento de 4 puntos en la puntuación total desde el inicio. La toma de la medicación de rescate o tratamiento de referencia prescrito por el investigador, serán considerados como empeoramiento.
3) Tiempo transcurrido hasta la primera manifestación de empeoramiento del Índice de calidad de vida dermatológica (DLQI) hasta la semana 48 definido como un aumento de 4 puntos en la puntuación total desde el inicio. La toma de la medicación de rescate o tratamiento de referencia prescrito por el investigador, serán considerados como empeoramiento.
4) Remisión mantenida, definida como la obtención de una puntuación de GPPGA de 0 o 1 (remisión total o casi total) en todas las visitas del paciente hasta la semana 48, sin uso de medicación de rescate o tratamiento de referencia prescrito por el investigador.
5) Aparición de acontecimientos adversos surgidos durante el tratamiento (AAT)

E.5.2.1

Timepoint(s) of evaluation of this end point

1) up to week 48
2) up to week 48
3) up to week 48
4) up to week 48
5) up to week 48

1) hasta la semana 48
2) hasta la semana 48
3) hasta la semana 48
4) hasta la semana 48
5) hasta la semana 48

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

Yes

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

Yes

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

Yes

E.7.3

Therapeutic confirmatory (Phase III)

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

Yes

E.8.1.5

Parallel group

Yes

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

E.8.2.2

Placebo

Yes

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Argentina

Australia

Belgium

Brazil

Chile

China

Czech Republic

Egypt

France

Germany

Greece

Italy

Japan

Korea, Republic of

Malaysia

Mexico

Netherlands

New Zealand

Poland

Russian Federation

Singapore

Spain

Taiwan

Thailand

Tunisia

Turkey

United States

Vietnam

E.8.7

Trial has a data monitoring committee

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

The trial will be considered complete when the last patient completes the last follow-up visit.

El ensayo se considerará finalizado cuando el último paciente haya finalizado la última visita de seguimiento.

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

E.8.9.2

In all countries concerned by the trial days

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

Yes

F.1.1

Number of subjects for this age range:

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

Yes

F.1.1.6.1

Number of subjects for this age range:

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

F.4.2.2

In the whole clinical trial

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

None

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2020-01-24

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2019-12-13

P. End of Trial
P.	End of Trial Status	Completed
P.	Date of the global end of the trial	2022-12-20

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials